Laboratory Monitoring Recommendations for Chronic Kidney Disease

Monitoring Frequency and Core Parameters

Additional Laboratory Tests for CKD Complications (eGFR < 60 mL/min/1.73 m²)

Interpretation of Expected Laboratory Changes with Therapy

Diabetes‑Specific Monitoring

Monitoring for Patients on Renin‑Angiotensin System Blockers

Safety and Avoidance of Nephrotoxins

Definition of Chronic Kidney Disease Chronicity

Albuminuria Versus Proteinuria

CKD Monitoring and Management

Core Monitoring Parameters

• The American Diabetes Association recommends monitoring eGFR and albuminuria (UACR) at least annually in all patients with CKD, with more frequent testing every 3-5 months for stage 4 CKD (eGFR 15-29 mL/min/1.73 m²) and every 1-3 months for stage 5 CKD (eGFR <15 mL/min/1.73 m²) 4, 5, 6
• eGFR should be calculated using a prediction equation, such as CKD-EPI, rather than relying on serum creatinine alone 7
• Albuminuria assessment via spot urine albumin-to-creatinine ratio (UACR) is preferred over 24-hour urine collections for convenience and accuracy 7

Monitoring Frequency by CKD Stage

• For stage 3 CKD (eGFR 30-59 mL/min/1.73 m²), monitoring should be done every 6-12 months 4, 5
• For stage 4 CKD (eGFR 15-29 mL/min/1.73 m²), monitoring should be done every 3-5 months 4, 5
• For stage 5 CKD (eGFR <15 mL/min/1.73 m²), monitoring should be done every 1-3 months 4, 5

Additional Laboratory Monitoring

• Serum potassium must be monitored in all patients on ACE inhibitors, ARBs, or diuretics due to risk of hyperkalemia or hypokalemia 4, 5
• Serum electrolytes should be monitored to assess for metabolic acidosis 4, 5
• Serum calcium and phosphate should be monitored for metabolic bone disease screening 4, 5
• Parathyroid hormone (PTH) and vitamin 25(OH)D should be monitored when eGFR falls below 60 mL/min/1.73 m² 4, 5

High-Risk Populations Requiring More Frequent Monitoring

• The American Journal of Kidney Diseases recommends increasing monitoring frequency beyond the standard schedule for patients with recent initiation or dose adjustment of hemodynamically active medications, rapid eGFR decline, or doubling of UACR on subsequent testing 6
• Patients with diabetes and ACR ≥300 mg/g should be monitored for 30% reduction in albuminuria as treatment target 6

Clinically Significant Changes Requiring Evaluation

• A >20% decline in eGFR on subsequent testing exceeds expected variability and warrants investigation 6
• A >30% decline in eGFR after initiating hemodynamically active therapies exceeds expected variability and requires evaluation 6, 8
• Doubling of UACR on subsequent testing exceeds laboratory variability and warrants evaluation 6

Special Considerations for Diabetes

• Annual screening with both eGFR and UACR is mandatory for all patients with diabetes, regardless of CKD stage 4, 5, 6
• Consider adding SGLT2 inhibitors or nonsteroidal mineralocorticoid receptor antagonists if residual albuminuria persists despite RAS inhibitor therapy 6
• Initial eGFR declines of ≤30% with SGLT2 inhibitors are expected and should not prompt discontinuation 6, 8

Assessment and Monitoring of Kidney Function in Severe Albuminuria

Interpretation of Laboratory Markers

• A mildly elevated blood urea nitrogen (BUN) level should be interpreted in conjunction with estimated glomerular filtration rate (eGFR) to gauge the severity of kidney dysfunction. 9
• First‑morning urine specimens are recommended for the most reliable albumin‑to‑creatinine ratio (ACR) measurement. 9

Thresholds for Decline in eGFR

• A reduction of more than 20 % in eGFR on follow‑up testing exceeds normal variability and warrants investigation for underlying causes. 9
• A decline of more than 30 % after starting hemodynamically active therapies (e.g., renin‑angiotensin system blockers) should prompt evaluation for volume depletion or other contributing factors. 9

Clinical Practice Recommendations

• Clinicians should not rely solely on BUN to assess renal function; eGFR calculation is essential for accurate staging and management. 9